Ceftazidime

Generic Name: Ceftazidime

Brand Names: Avycaz, Fortaz, Tazicef, Zavicefta

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₂N_₆O_₇S_₂

CAS Number: 72558-82-8

Unique Ingredient Identifier: DZR1ENT301

Background: Bacteria possess a cell wall comprising a glycopeptide polymer commonly known as peptidoglycan, which is synthesized and remodelled through the action of a family of enzymes known as "penicillin-binding proteins" (PBPs). β-lactam antibiotics, including cephalosporins, are PBP inhibitors that, through inhibition of essential PBPs, result in impaired cell wall...

Indication: Ceftazidime is indicated for the treatment of lower respiratory tract infections, skin and skin structure infections, urinary tract infections, bacterial septicemia, bone and joint infections, gynecologic infections, intra-abdominal infections (including peritonitis), and central nervous system infections (including meningitis) caused by susceptible bacteria...

Associated Conditions: Bacteremia, Bacterial Infections, Bacterial Septicemia, Bone and Joint Infections, Bronchopulmonary Infection, Central Nervous System Infections, Complicated Intra-Abdominal Infections (cIAIs), Complicated Skin and Soft Tissue Infection, Complicated Urinary Tract Infection, Complicated Urinary Tract Infections caused by susceptible Gram-negative microorganisms, Fever caused by susceptible bacteria, Gynecological Infection, Intraabdominal Infections, Lower Respiratory Tract Infection (LRTI), Meningitis, Bacterial, Nosocomial Pneumonia, Peritoneal Dialysis Associated Peritonitis, Skin and skin structure infections, Urinary Tract Infection, Ventilator-associated Bacterial Pneumonia caused by susceptible Gram-negative microorganisms, Chronic suppurative Otitis media, Hospital-acquired bacterial pneumonia caused by susceptible Gram-negative microorganisms, Malignant Otitis Externa, Susceptible Intra-Abdominal Infection caused by susceptible Gram-negative microorganism

Associated Therapies: -

Clinical Trials

Daptomycin + Meropenem Versus Ceftazidime in the Treatment of Nosocomial Spontaneous Bacterial Peritonitis

Phase 2

Terminated

Conditions: Cirrhosis
Nosocomial Spontaneous Bacterial Peritonitis
Ascites

Interventions: Drug: Daptomycin + Meropenem
Drug: Ceftazidime

First Posted Date: 2011-10-19

Last Posted Date: 2014-10-15

Lead Sponsor: University of Padova

Target Recruit Count: 32

Registration Number: NCT01455246

Locations: 🇮🇹
Dept. of Clinical and Experimental Medicine, University of Padova, Padova, PD, Italy

A Study to Assess the Levels of Two Antibiotics in the Blood When Given Together and Separately

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: CAZ104
Drug: Avibactam
Drug: Ceftazidime

First Posted Date: 2011-09-09

Last Posted Date: 2017-09-01

Lead Sponsor: Pfizer

Target Recruit Count: 43

Registration Number: NCT01430910

Locations: 🇬🇧
Research site, London, United Kingdom

Population Pharmacokinetics of Anti-infectious Drugs in Children

Not Applicable

Completed

Conditions: Ceftazidime
Ciprofloxacin
Pediatrics
Voriconazole

Interventions: Drug: Ceftazidime
Drug: Voriconazole
Drug: Ciprofloxacin

First Posted Date: 2011-04-29

Last Posted Date: 2015-03-18

Lead Sponsor: University Hospital, Bordeaux

Target Recruit Count: 214

Registration Number: NCT01344512

Locations: 🇫🇷
APHP - Hôpital NEcker, Paris, France
🇫🇷
CHU Poitiers, Poitiers, France
🇫🇷
CHU de Dijon, Dijon, France

and more 11 locations

A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of Ceftazidime NXL104 or Ceftaroline Fosamil NXL104, Compared With Placebo, Using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy Male Volunteers

Interventions: Drug: Placebo Infusion
Drug: NXL104
Drug: Moxifloxacin
Drug: Ceftaroline
Drug: Ceftazidime

First Posted Date: 2011-02-07

Last Posted Date: 2017-09-01

Lead Sponsor: Pfizer

Target Recruit Count: 54

Registration Number: NCT01290900

Locations: 🇺🇸
Research Site, Overland Park, Kansas, United States

Duration of Antibiotics in Infective Exacerbations of Cystic Fibrosis

Phase 4

Conditions: Cystic Fibrosis

Interventions: Drug: Ceftazidime
Drug: Tobramycin
Drug: Meropenem

First Posted Date: 2010-01-08

Last Posted Date: 2010-04-13

Lead Sponsor: Imperial College London

Target Recruit Count: 240

Registration Number: NCT01044719

Locations: 🇬🇧
Department of Cystic Fibrosis, Royal Brompton Hospital, London, United Kingdom

Safety and Efficacy of IV CXA-101 and IV Ceftazidime in Patients With Complicated Urinary Tract Infections

Phase 2

Completed

Conditions: Complicated Urinary Tract Infection

Interventions: Drug: CXA-101
Drug: Ceftazidime

First Posted Date: 2009-06-16

Last Posted Date: 2018-10-18

Lead Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Target Recruit Count: 129

Registration Number: NCT00921024

Locations: 🇵🇱
Szpital Bielański im.Ks. Jerzego Popiełuszki Samodzielny Publiczny Zakład Opieki Zdrowotnej IV Kliniczny Oddzial Chorób Wewnętrznych, Warszawa, Poland
🇵🇱
Szpital Praski p.w. Przemienienia Pańskiego Samodzielny Publiczny Zakład Opieki Zdrowotnej ll Oddział Wewnętrznych, Warszawa, Poland
🇵🇱
Samodzielny Publiczny Szpital Wojewódźki im. Papieża Jana Pawła ll Oddział Wewnętrznych Nefrologiczno-Endokrynologiczny ze Stacją Dializ, Zamość, Poland

and more 18 locations